Edoxaban outperforms enoxaparin sodium in a late-stage trial

12/8/2010 | Genetic Engineering News

A Phase III study found that Daiichi Sankyo's once-daily oral anti-clotting drug edoxaban outperformed enoxaparin sodium, a twice-daily injectable treatment, in preventing venous thromboembolic events among patients who underwent total hip-replacement surgery. Edoxaban, which acts as a direct factor Xa inhibitor, also proved superior in cutting the incidence of an elevated level of serum aminotransferase, a marker of liver damage.

View Full Article in:

Genetic Engineering News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations